Therapeutic | Prezalumab |
Target | ICOSLG |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK |
100% seqID Fv Structure | 6x4t [Fvs: BE, DF] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6x4t [Fvs: BE, DF] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2015 |
INN Year Recommended | 2016 |
Companies Involved | Amgen, MedImmune |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Cutaneous lupus erythematosus, Psoriasis, Sjogren's syndrome, Systemic lupus erythematosus |
Notes | May have had a former name of Prezalizumab |